Zacks Investment Research Lowers Apricus Biosciences, Inc (APRI) to Sell

Apricus Biosciences, Inc (NASDAQ:APRI) was downgraded by Zacks Investment Research from a “buy” rating to a “sell” rating in a report issued on Tuesday, November 7th.

According to Zacks, “Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT ┬«. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT┬« drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California. “

Separately, HC Wainwright set a $4.00 price objective on shares of Apricus Biosciences and gave the stock a “buy” rating in a research report on Thursday, August 3rd.

Shares of Apricus Biosciences (NASDAQ:APRI) traded up $0.01 on Tuesday, hitting $1.61. 37,862 shares of the company traded hands, compared to its average volume of 156,395. Apricus Biosciences has a fifty-two week low of $0.86 and a fifty-two week high of $4.07.

Apricus Biosciences (NASDAQ:APRI) last posted its quarterly earnings results on Thursday, November 2nd. The company reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.15). During the same period in the prior year, the firm earned ($0.19) EPS. research analysts forecast that Apricus Biosciences will post -0.6 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was published by BBNS and is the sole property of of BBNS. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://baseballnewssource.com/markets/zacks-investment-research-lowers-apricus-biosciences-inc-apri-to-sell/1763770.html.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Get a free copy of the Zacks research report on Apricus Biosciences (APRI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with our FREE daily email newsletter.

 


Latest News

Phillies Sign Free Agent Carlos Santana
Phillies Sign Free Agent Carlos Santana
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle


Leave a Reply

 
© 2006-2017 BBNS.